Camlin Fine Sciences

June 25, 2025

To,	To,
BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	Listing Department, **National Stock Exchange of India Ltd**., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol**:** CAMLINFINE || Series: EQ

Sub: **Update on Disclosure made pursuant to the Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'SEBI Listing Regulations')**

Dear Sir/Madam,

This is in furtherance to our earlier disclosure dated February 24, 2025, pertaining to the proposed acquisition of a majority stake in Vinpai S.A. ("**Vinpai**") pursuant to the Share Purchase Agreement ("**SPA**") executed between the Company and certain significant shareholders of Vinpai, including its founders ("**Sellers**").

In the aforesaid disclosure, the Company had indicated the expected timeline for completion of the acquisition as on or before June 30, 2025. We hereby inform that the timeline for completion of the said acquisition has been extended mutually by the parties and is now expected to be completed on or before September 30, 2025. The delay is on account of the Sellers, being foreign nationals, who are currently in the process of procuring certain pre-mandatory documentation, such as obtaining Permanent Account Number (PAN) and opening of a demat account, which is a requisite for preferential allotment in accordance with the conditions prescribed under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Further, in accordance with the SPA, the Company has invested €3.3 million in Vinpai through subscription to listed secured convertible bonds issued by Vinpai. These bonds were initially set to mature within six (6) months from the date of issuance. However, since the share acquisition process is still underway, the maturity date of these convertible bonds has been extended to October 25, 2025, mutually by the parties.

The relevant details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were provided in our prior disclosure dated February 24, 2025.

You are requested to take the above on record and treat the same as compliance with applicable provisions of the SEBI Listing Regulations.

Thanking You,
For Camlin Fine Sciences Limited

Rahul Sawale

Digitally signed by Rahul Sawale
DN: c=IN, o=Personal,CID - 6936121,
pseudonym=20231124120211345,
2.5.4.20=dfd09c2630663c42dd1f2f308aefc8b4e67435d64ee22beae79ca105aa72c4bb, postalCode=410210,
st=Maharashtra, title=2272,
serialNumber=135c0bee894849d2afa044f6b08812148dc146ae18fd209897eaeebb28cf8aa7, cn=Rahul Sawale
Date: 2025.06.25 09:07:29 +05'30'

Rahul Sawale
Company Secretary & VP Legal